G&A at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's G&A?
- Corvus Pharmaceuticals (CRVS) reported G&A of $3.7M in Q1 2026.
- How has Corvus Pharmaceuticals's G&A changed year-over-year?
- Corvus Pharmaceuticals's G&A increased by 49.9% year-over-year, from $2.47M to $3.7M.
- What is the long-term trend for Corvus Pharmaceuticals's G&A?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's G&A has grown at a -0.7% compound annual growth rate (CAGR), from $9.52M to $9.25M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.